CLDI vs CLRB

Calidi Biotherapeutics, Inc. vs Cellectar Biosciences, Inc. — Valuation Comparison 2026

CLDI

Biotechnology
Calidi Biotherapeutics, Inc.
Quality
4.2
out of 10
Value Trap
39
LOW
Price
$0.19
Last close
Models
6/13
Active
VS

CLRB

Biotechnology
Cellectar Biosciences, Inc.
Quality
3.7
out of 10
Value Trap
27
LOW
Price
$3.14
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CLDI Fair ValueCLDI Upside CLRB Fair ValueCLRB Upside
Bayesian DCF Intrinsic $0.18 -7.4% $1.39 -55.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.04 +448.0% $0.17 -93.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CLDI vs CLRB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CLDI vs CLRB — Which Stock Is More Undervalued?

CLDI scores higher with a 4.2/10 quality rating vs CLRB's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Calidi Biotherapeutics, Inc. (CLDI) and Cellectar Biosciences, Inc. (CLRB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CLDI currently trades at $0.19 with a QOC of 4.2/10, while CLRB trades at $3.14 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).